Duofer-Fol

Quick links to important sections

Duofer-Fol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duofer-Fol

Property Description
Active ingredient Ferrous Fumarate, Ferrous Gluconate, Folic Acid
Form Oral Tablet
Pharmacological class Hematopoietics / Antianemics
Common use Correcting dual iron and folate deficiencies
Origin Synthetic

What Type of Preparation is Duofer-Fol?

Duofer-Fol is an antianemic medicine that is classified as a fixed-dose combination vitamin and mineral preparation within the broader pharmacological group of hematopoietics. This formulation is supplied as an oral tablet, representing a synthetic and orally administered compound designed for systemic action. This type of preparation is clinically recognized for its efficacy in rapidly normalizing blood parameters when dual deficiencies are identified.

Its design as a combination product distinguishes it from single-ingredient supplements, making it a targeted therapeutic choice for patient groups where both essential micronutrients are known to be lacking.

Core Composition: Iron Salts and Folic Acid

The unique strength of Duofer-Fol lies in the synergy of its three active ingredients: Ferrous Fumarate, Ferrous Gluconate, and Folic Acid (Vitamin B9). A differentiating factor is the strategic inclusion of two distinct organic iron salts to deliver bivalent iron (Fe^2+). This dual-salt approach is intended to potentially optimize oral bioavailability while aiming to reduce the gastrointestinal distress sometimes associated with high-dose single-iron preparations.

The Folic Acid component is included because it is an indispensable hematopoietic factor that is required for DNA synthesis in blood precursor cells.

General Purpose: Addressing Dual Nutritional Needs

The general therapeutic purpose of Duofer-Fol is the correction of coexisting iron deficiency and Folic Acid deficiency. This simultaneous replenishment ensures that the body receives both the necessary mineral for hemoglobin synthesis (iron) and the vitamin co-factor required for new red blood cell maturation (folate). This combined mechanism supports the body in restoring its capacity for effective oxygen transport.

Regulatory References

  1. Folate Fact Sheet for Health Professionals

What side effects are possible with Duofer-Fol?

Officially Documented Adverse Reactions

The primary pattern of side effects reported with this iron and folic acid combination product involves the Gastrointestinal System. Reactions classified as Common in regulatory documentation include nausea, vomiting, diarrhea, constipation, and stomach or abdominal pain. A related, expected occurrence is a change in the color of the stools, typically presenting as a black or dark color, which is a harmless consequence of unabsorbed iron.

Reactions categorized under Immune System Disorders are documented with a Rare or Not known frequency. These potential reactions may include skin manifestations such as rash or pruritus (itching), and in rare instances, more severe reactions such as anaphylaxis have been reported.


General Safety Considerations and Contraindications

One critical safety consideration across regulatory documents is the risk of acute iron poisoning following accidental ingestion, which is documented as potentially fatal, particularly in young children.

Safety labeling also specifies conditions under which the medication must not be used (contraindications). These include documented states of iron overload (such as haemochromatosis or haemosiderosis) and anemias that are not caused by iron deficiency, such as pernicious anemia or haemolytic anaemia.

Regulatory notes also advise caution in patients with specific active gastrointestinal conditions, including active peptic ulceration, regional enteritis, and ulcerative colitis. Furthermore, some regulatory labels state that use during the first trimester of pregnancy is not recommended.

Overdose and Emergency Response

Overdose of Duofer-Fol is primarily defined by the severe toxicity profile of its iron salt components, which official regulatory documents classify as a potentially lethal medical emergency. Due to the high risk and staged progression of toxicity, it is mandatory to seek immediate medical attention and contact emergency services immediately upon suspicion of overdose.

Documented Manifestations and Severe Outcomes

Initial manifestations of an acute overdose typically involve severe gastrointestinal distress, including persistent vomiting (which may contain blood), severe abdominal pain, and bloody diarrhea. As the toxicity progresses, systemic effects such as lethargy, pallor, shock, and metabolic acidosis may develop. Severe outcomes officially documented in regulatory labeling include cardiovascular collapse, hepatic failure, and subsequent coma or death.

Required Emergency Actions

Overdose carries a particularly heightened and potentially lethal risk in young children. The regulatory profile confirms the availability of a specific intervention for severe cases: the use of the chelating agent Deferoxamine. Required management includes continuous hospital observation, diagnostic testing (such as measuring serum iron levels), symptomatic and supportive treatment, and in some cases, procedures like gastric decontamination or whole-bowel irrigation to manage the established toxic effects.

Therapeutic Uses of Duofer-Fol

This preparation is commonly used in clinical situations where patients have a diagnosed coexisting deficiency of both iron and folic acid (Vitamin B9). Its primary therapeutic use is the treatment of iron-deficiency anaemia and the prevention of iron and folic acid deficiency, mainly during pregnancy. It is applied in addressing anemia that arises from this dual nutritional deficit and is relevant in conditions where functional stability becomes affected by this deficit.

This preparation is relevant in conditions characterized by periods of heightened symptoms, including anemia and periods requiring supplemental support. The key indications for this combination include treating established deficiency-driven anemia and providing supportive assistance during periods of high physiological stress.

Duofer-Fol is relevant for managing the cluster of chronic tiredness, profound weakness, and lack of staminasymptoms that interfere with daily functioning. The therapeutic benefit assists with maintaining functional stability, and supports general well-being during symptomatic phases related to systemic imbalance.

“The combination is commonly used in clinical settings that involve acute or unstable symptom patterns, such as during pregnancy and breastfeeding, in situations where patients experience increased physiological stress.”

Support During Periods of Heightened Physiological Demand

The medication is also relevant when supportive symptom management is appropriate, particularly in patients dealing with chronic blood loss or inadequate dietary intake. This provides supportive relief and contributes to easing the overall symptom load in situations involving recurrent or episodic manifestations.

Quick Fact: Relief for Fatigue and Weakness

This preparation helps manage symptoms of systemic imbalance, such as profound fatigue and lack of energy, allowing patients to cope more steadily with symptom fluctuations.

Regulatory References

  1. World Health Organization (WHO) guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Duofer-Fol?

Eligibility for Duofer-Fol is determined by specific regulatory criteria, focusing on existing medical conditions and patient demographics as established in official labeling.


Contraindicated Populations

Use of this medicine is absolutely contraindicated in patients with certain conditions, including:

  • Iron Overload: Individuals diagnosed with iron overload disorders like hemochromatosis or hemosiderosis.
  • Anaemia Type: Patients with anaemias other than those caused by iron deficiency, such as pernicious anaemia or undiagnosed B12 deficiency.
  • Hypersensitivity: Known allergy or hypersensitivity to Ferrous Fumarate, Folic Acid, or any components.
  • Gastrointestinal: Patients with an active peptic ulcer.

Age and Conditional Use Rules

Population Group Regulatory Status
Children under 12 years Not recommended
Older Adults (Elderly) Use is appropriate
Pregnancy (First Trimester) Not recommended
Pregnancy (2nd/3rd Trimesters) Use is appropriate

The medicine's use requires caution in patients with a history of peptic ulcers or chronic inflammatory bowel disease, and for patients with folate-dependent tumors. Concomitant use with parenteral iron is prohibited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Duofer-Fol is defined by the properties of its active ingredients, primarily involving changes in drug exposure and specific prohibited combinations documented in regulatory sources.

Contraindicated Combinations The co-administration of Duofer-Fol is formally contraindicated with Dimercaprol due to the risk of forming toxic complexes. The combination with Parenteral Iron is also prohibited to avoid severe iron poisoning risk.

Exposure-Altering Interactions (Reduced Bioavailability) Iron components can chelate with, and reduce the systemic exposure of, several medicinal products, including Quinolone antibiotics, Tetracycline antibiotics, Levothyroxine, Bisphosphonates, and Penicillamine. Conversely, the Folic Acid component may lead to reduced plasma concentrations and efficacy of certain anticonvulsants, such as Phenytoin and Phenobarbital, via metabolic alteration.

Mandatory Administration Timing To mitigate the effects of chelation and reduced absorption, regulatory bodies require specific administration spacing. Iron-containing products must be separated from Levothyroxine by at least 4 hours. Separation by at least 2 to 3 hours is required for Quinolone and Tetracycline antibiotics. Separation by at least 2 hours is also required for Calcium or Magnesium salts (antacids/supplements).

Other Documented Conflicts Folic Acid may interfere with the antifolate action of high-dose Methotrexate, reducing its therapeutic effect. Regarding non-drug substances, iron absorption is significantly reduced by components in certain foods (dairy products, whole-grain cereals, tea, and coffee). Official labeling notes that high-dose Folic Acid can mask the haematological signs of coexisting Vitamin B12 deficiency, a particular consideration in elderly patients.

Mechanism of Action

How Duofer-Fol Works: Mechanism of Action

Duofer-Fol operates via nutrient agonism, directly supplying the precursors iron and folate to their respective molecular pathways. This dual resource replenishment overcomes stoichiometric limitations that constrain several fundamental biosynthetic processes.

The mechanism simultaneously engages two major, functionally linked intracellular cascades. Iron is incorporated into the Heme Synthesis Pathway as a structural component of hemoglobin. Concurrently, folate is metabolized into cofactors required for Nucleic Acid Synthesis, specifically providing single-carbon units essential for generating purines and pyrimidines (DNA/RNA building blocks).

This combined action provides the necessary input for both rapid cell division (mitosis) and required protein formation within erythroid precursors in the bone marrow. The synergy supports an integrated physiological response that facilitates robust red blood cell production, leading to the formation of functional erythrocytes and a corresponding change in systemic oxygen transport capacity due to the increased quantity of functional hemoglobin.

Dosage and Administration Information

Duofer-Fol is administered exclusively via the oral route as a tablet. The recommended dosing schedule for both the treatment of diagnosed deficiency anemia and its prophylaxis is one tablet once daily (OD). This once-daily frequency is consistent across adult patient populations, including those receiving support during pregnancy.

To achieve optimal absorption of the active ingredients, the tablet is typically taken on an empty stomach, separated by at least one hour before or two hours after a meal. If gastric upset occurs, administration with food is permitted to enhance tolerance. The tablet must be swallowed whole with a full glass of water and should not be crushed or chewed. Patients are instructed to avoid lying down for at least ten minutes after taking the dose.

A critical administration constraint involves separating the dose from absorption inhibitors. Concurrent intake of antacids, dairy products, tea, or coffee must be avoided within a two-hour window of taking the medicine. For duration, treatment for established anemia continues until hemoglobin levels normalize, followed by several weeks of continued administration to adequately replenish body iron stores. If a dose is missed, the standard protocol is to return to the regular schedule the following day without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Duofer-Fol


Evidence for Preventing Iron Deficiency and Anemia During Pregnancy

This section will summarize the available evidence, primarily from randomized controlled trials and systematic reviews, focusing on the use of iron and folic acid supplementation to influence blood parameters in women during and leading up to pregnancy.

Combination preparations containing iron and folic acid was evaluated in numerous Randomized Controlled Trials (RCTs). Researchers evaluated the impact on maternal hematological status, specifically by monitoring the concentration of hemoglobin and the prevalence of anemia and iron deficiency at the time of delivery.

Pooled analyses of trials tracked maternal hemoglobin levels at term, and researchers reported differences in measurements between groups receiving iron/folate and control groups. Findings were mixed regarding certain neonatal outcomes such as preterm birth, and the data for these outcomes was observed in some studies to be associated with low certainty.

What remains uncertain is the effect of the specific dual iron salt combination (Ferrous Fumarate and Ferrous Gluconate) found in Duofer-Fol, as the majority of large-scale evidence focuses on single iron salt formulations. Also, long-term effects are not fully established for both the mother and child beyond the immediate delivery period in the research.


Evidence for the Treatment of Iron Deficiency Anemia (IDA)

This part will cover the clinical study landscape for using these preparations to influence hematological markers related to diagnosed anemia, detailing the types of trials that examined the change in blood biomarkers like hemoglobin and ferritin.

Research has explored the use of iron and folic acid preparations for adults and pregnant women with diagnosed Iron Deficiency Anemia (IDA). Key outcomes monitored included the change in Hemoglobin (Hb) and Serum Ferritin levels over the study period. Trials described consistent measurements of increases in hemoglobin concentration and serum ferritin levels following the observed intervention.

Comparative evidence is lacking for this specific dual-salt combination against other single-salt iron supplements, as research often focuses on standard oral ferrous salts. Follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes related to maintaining iron stores after the treatment phase ends or preventing recurrence.

Key Studies & References

  1. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis
  2. Treatment and prevention of anemia with ferrous sulfate plus folic acid in children attending daycare centers in Goiânia, Goiás State, Brazil: a randomized controlled trial
  3. Treatment strategies for non-responders to oral iron and folic acid treatment in anemic children: A systematic review
  4. Effectiveness of Dietary Interventions to Treat Iron-Deficiency Anemia in Women: A Systematic Review of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Duofer-Fol (FAQ)


Q: Can Duofer-Fol interfere with my thyroid medication?

A: Yes, official regulatory labeling indicates that iron-containing products can interfere with the absorption and effectiveness of certain thyroid medications, such as levothyroxine. Regulatory guidance recommends separating the dose of Duofer-Fol from your thyroid medication by at least four hours.


Q: Is it safe to take Duofer-Fol with vitamin C supplements?

A: Regulatory documentation often notes that Vitamin C (ascorbic acid) can actually favor the absorption of iron in the digestive system. The administration timing of any supplements should be discussed.


Q: Can children take Duofer-Fol, and what age is appropriate?

A: Official product information states that Duofer-Fol is generally not recommended for use in children under 12 years of age.


Q: Is Duofer-Fol suitable for pregnant women?

A: According to official regulatory guidance, the use of Duofer-Fol is not recommended during the first trimester of pregnancy. However, its use is generally considered appropriate during the second and third trimesters to manage or prevent deficiencies.


Q: How long does it usually take for Duofer-Fol to correct an iron deficiency?

A: Regulatory guidance on treatment duration indicates that therapy for established anemia continues until hemoglobin levels return to normal. Following this, the medicine is continued for several weeks to ensure body iron stores (ferritin) are adequately replenished.


Q: Does Duofer-Fol interact with antacids or heartburn medication?

A: Yes, iron-containing products can interact with antacids and supplements containing calcium or magnesium salts. Regulatory bodies require a separation of the Duofer-Fol dose from these products by at least two hours to minimize reduced absorption of the iron.


Q: Can I crush or chew Duofer-Fol tablets?

A: No, official product instructions state that the tablet must be swallowed whole with a full glass of water. It should not be crushed, broken, or chewed.


Q: Can I take Duofer-Fol if I have a sensitive stomach?

A: The formulation is designed with two distinct iron salts to potentially optimize iron uptake while aiming to reduce the stomach upset sometimes associated with high-dose iron. If gastric upset occurs, the official guidance permits taking the tablet with food to enhance tolerance.


Q: Is it normal to feel nauseous when taking Duofer-Fol?

A: Yes, nausea is classified as a Common adverse reaction documented in the regulatory labeling for this type of product. Gastrointestinal side effects like nausea, constipation, and diarrhea are the most frequently reported issues.


Q: Are there different strengths of Duofer-Fol tablets?

A: The official product information typically lists a fixed dose of the active ingredients—Ferrous Fumarate, Ferrous Gluconate, and Folic Acid—corresponding to a single strength. This single strength is the standard offering in the regions where the product is regulated.


Q: Why would someone need to take Duofer-Fol for a long time?

A: Regulatory and clinical guidance states that therapy extends beyond the correction of blood parameters like hemoglobin. Continued administration for several weeks or months may be recommended to fully replenish the body's stored iron (ferritin) and help prevent recurrence of deficiency.


Q: Is it possible to be allergic to Duofer-Fol?

A: Yes, hypersensitivity (allergy) to any component of the medication is listed as a contraindication for use. While rare, more severe reactions such as rash, itching (pruritus), and anaphylaxis have been reported in regulatory documents.


Q: Does Duofer-Fol need to be stored in the refrigerator?

A: No, official storage guidelines specify that the medicine must be stored at a controlled room temperature, typically below 25°C. It must not be refrigerated or frozen to maintain its stability.


Q: What clinical evidence supports the use of Duofer-Fol for iron deficiency?

A: Regulatory bodies rely on evidence from Randomized Controlled Trials (RCTs) and systematic reviews. These studies evaluate the use of iron and folic acid preparations for treating Iron Deficiency Anemia (IDA) by tracking increases in important blood markers like Hemoglobin (Hb) and Serum Ferritin levels.


Q: Does Duofer-Fol interact with coffee or tea?

A: Yes, regulatory guidelines advise avoiding the consumption of tea and coffee within a two-hour window of taking the medicine. Components in these beverages significantly reduce the absorption of the iron in Duofer-Fol.


Q: Are there any studies comparing Duofer-Fol to other iron supplements?

A: Official regulatory guidance states that comparative evidence is often lacking for this specific dual-salt combination (Ferrous Fumarate and Ferrous Gluconate) against other single-salt iron supplements.


Q: What are the less common, but more serious, side effects to watch out for with Duofer-Fol?

A: While rare, regulatory documents mention certain serious side effects that have been reported. These include skin reactions such as rash or intense itching, and in very rare instances, severe allergic reactions like anaphylaxis.


Q: Can older adults take Duofer-Fol safely?

A: Official regulatory labeling designates the use of Duofer-Fol as appropriate for the older adult (elderly) population.


Q: Can taking too much Duofer-Fol be dangerous?

A: Yes, regulatory safety considerations highlight a critical risk of acute iron poisoning following accidental ingestion. This is documented as potentially fatal, particularly if ingested by young children.


Q: Is the iron in Duofer-Fol easily absorbed?

A: The formulation contains two distinct organic iron salts—Ferrous Fumarate and Ferrous Gluconate. This dual-salt approach is used to potentially optimize the oral bioavailability of the iron component.

How should Duofer-Fol be stored and disposed of?

How to Store and Dispose of Duofer-Fol?

The storage and disposal of Duofer-Fol (Ferrous Fumarate and Folic Acid tablets) must strictly follow official regulatory guidelines to maintain its stability and ensure public safety.

️ Required Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, typically below 25°C.
Protection The tablets must be protected from light and moisture.
Container Rule Keep the product in the original container and ensure it is tightly closed.
Prohibition The medicine must not be refrigerated or frozen.
Child Safety Keep Duofer-Fol out of the sight and reach of children due to the serious risk of iron poisoning.

️ Official Disposal

Unused or expired product must be handled as pharmaceutical waste. Do not dispose of the medicine in household trash or via the toilet/sink (wastewater). The product should be returned to a pharmacy or designated collection point for disposal according to local regulatory waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duofer-Fol found in:

A-Z Index: